恩瑞格是治疗什么病症的？

(Deferasirox) is clinically used for patients with iron accumulation due to long-term blood transfusion (such as those suffering from thalassemia or other rare anemias). It is a new type of ferric iron chelator with high oral absorption rate. The drug metabolism half-life is 8 to 16 hours. It reaches the blood peak at 24 hours. The concentration reaches a stable state after 3 days. After metabolism, it is mainly excreted in the feces.

The recommended starting daily dose of Deferasirox is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. In patients who have already responded well to deferoxamine therapy, an initial dose of Deferasirox equivalent to half the deferoxamine dose may be considered. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days per week, or equivalent, may start at 20 mg/kg if switched to Deferasirox.)

How to take: Deferasirox should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Deferasirox should not be taken with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before taking. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

There have been no reports of interactions between Deferasirox and other medications. However, because Deferasirox binds to metal cations, there is a potential for drug interactions when Deferasirox is combined with drugs containing trivalent cations (such as antacids containing aluminum ions). There are no formal studies on the safety of taking Deferasirox with vitamin C. Based on reports of adverse interactions with Deferasirox and vitamin C, caution should be used when taking these two medications together.